Gujarat Kidney & Super Speciality Ltd
Gujarat Kidney & Super Speciality Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Get Gujarat Kidney & Super Speciality Ltd's next results in your feed
Top 10 Healthcare Services companies on management guidance
See the sector's top 10 — free with your mobile number.
Gujarat Kidney & Super Speciality Ltd Q2 FY27 key numbers
- Revenue
- Q2 FY27 Revenue from Operations: ₹3,809 lakhs, +195% YoY.
As stated in Gujarat Kidney & Super Speciality Ltd's Q2 FY27 investor presentation · published 4 Nov 2026. Reported figures, not investment advice.
Based on Gujarat Kidney & Super Speciality Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Revenue from Operations: ₹3,809 lakhs, +195% YoY (Page 6, 7). Q2 FY27 Financials:.
From Gujarat Kidney & Super Speciality Ltd's Q2 FY27 earnings-call transcript · updated 4 Nov 2026.
How did Gujarat Kidney & Super Speciality's revenue grow in the September 2026 quarter?
- Q2 FY27 Revenue from Operations: ₹3,809 lakhs, +195% YoY (Page 6, 7)
- Q2 FY27 EBITDA: ₹1,022 lakhs, +99% YoY; EBITDA margin 26.8% (Page 6, 7)
- Q2 FY27 Profit After Tax (PAT): ₹660 lakhs, +129% YoY (Page 6, 7)
- Q2 FY27 OPD volume: 78,643 visits for H1 FY27, already 82% of FY26 full-year volumes (Page 20)
- Q2 FY27 IPD volume: 11,040 admissions for H1 FY27, already 83% of FY26 full-year volumes (Page 20)
2 more points from Gujarat Kidney & Super Speciality Ltd's call on revenue
Create a free account to keep reading this call
What happened to Gujarat Kidney & Super Speciality's margins in Q2 FY27?
See what Gujarat Kidney & Super Speciality Ltd said on profitability & margins — free account, 30 seconds.
What capex is Gujarat Kidney & Super Speciality planning?
- Investment of ₹623 lakhs in PP&E during H1 FY27 as part of ongoing inorganic expansion (Page 5).
- Newly acquired hospitals (Raj Palmland - Bharuch, Surya Hospital & ICU - Borsad, Ashwini Medical Centre - Anand) are being upgraded with super-speciality departments and expanded service offerings (Page 22).
- Establishment of new infrastructure including renal transplant units, 3D imaging for urology, and interventional cardiology departments planned at key hospitals (Page 22).
- Investment in advanced medical equipment such as laser systems, cardiac cath labs, laparoscopic and endoscopic instruments, and an IVF laboratory to enhance clinical capabilities (Page 22).
2 more points from Gujarat Kidney & Super Speciality Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Gujarat Kidney & Super Speciality raising money or cutting debt?
See what Gujarat Kidney & Super Speciality Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Gujarat Kidney & Super Speciality's order book?
See what Gujarat Kidney & Super Speciality Ltd said on order book & pipeline — free account, 30 seconds.
Gujarat Kidney & Super Speciality Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹34 Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
Others in Healthcare Services this season
- Krishna Institute of Medical Sciences (Q2 FY27)
13,630 million, up 41.3% YoY (Q2 FY26: Rs. Key investor presentation takeaways from Krishna Institute of Medical Sciences Ltd's Q2 FY27 investor presentation —
- Apollo Hospitals (Q2 FY27)
Q2 FY27 Revenue: ₹76,149 million (Consolidated), up 23% YoY from ₹61,888 million in Q2 FY26. Key investor presentation takeaways from Apollo Hospitals Enterpris
- Vimta Labs (Q2 FY27)
Export-import linked food testing volumes recovering with operations reaching 60%-70% of normal levels. Key concall takeaways from Vimta Labs Ltd's Q2 FY27…
- Dr Lal Pathlabs Ltd (Q2 FY27)
874 Cr, up 19.6% YoY from Rs. Key investor presentation takeaways from Dr Lal Pathlabs Ltd's Q2 FY27 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Gujarat Kidney & Super Speciality Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gujarat Kidney & Super Speciality Ltd Q2 FY27 results?
Q2 FY27 Revenue from Operations: ₹3,809 lakhs, +195% YoY (Page 6, 7). Q2 FY27 Financials:.
What is Gujarat Kidney & Super Speciality Ltd share price analysis?
Gujarat Kidney & Super Speciality Ltd currently shows a neutral. The stock trades at a P/E of 79.5 with a market cap of ₹1,259 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gujarat Kidney & Super Speciality Ltd planning capital expenditure?
Investment of ₹623 lakhs in PP&E during H1 FY27 as part of ongoing inorganic expansion (Page 5).
Keep Gujarat Kidney & Super Speciality Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.